readmarketresearchReport Information More information from: www.readmarket.com/industry-report/176003-Global-Duchenne-Muscular-Dystrophy-Drugs-Market |
Duchenne Muscular Dystrophy Drugs Market global analysis By Type, Application and Companies Forecast 2022-2027 (Market Size, Share & Trends with COVID-19 Impact Analysis)
Report Code:RMR176003 Publish Date: 2021-09-21
| Price | Single User PDF: $ 3250 | Enterprise PDF : $6500 |
Description:
Global Duchenne Muscular Dystrophy Drugs Market Overview
The global Duchenne Muscular Dystrophy Drugs market is expected to reach USD XX Million by the end of year 2027 from USD XX Million from the year 2021. In the span of last two years, Duchenne Muscular Dystrophy Drugs market has shown promising growth from both sides (Demand and Supply) and demand from end users is expected to rise continuously. It has also been observed that the Duchenne Muscular Dystrophy Drugs market has registered XX% of growth rate during 2016-2021 and is estimated to register XX% of CAGR during the period 2021 to 2027.
COVID 19 Impact on Duchenne Muscular Dystrophy Drugs Market
The COVID19 outbreak had a major impact on several industries on different levels; Some of these were border restrictions, transportation, and logistics restrictions, and worldwide bans. It also created economic uncertainty as the outbreak created a situation where both manufacturing and service industries were kept shut for very long period. Lack of availability of solution and the growing number of people infected with COVID and the uncertainty about the end of the crisis are much greater than with previous outbreaks. The pandemic has resulted in the closure of regions, border restrictions and the breakdown of transport networks.
Segment Analysis of Duchenne Muscular Dystrophy Drugs Market
This study on Duchenne Muscular Dystrophy Drugs market estimates and provides revenue growth at global, regional and country levels also, offers an overview of the latest developments in each of the sub-sectors from 2016 to 2027. For this analysis, READ Market Research has bifurcated the market of Duchenne Muscular Dystrophy Drugs into Type Segment, Application Segment and Regional Segment.
The companies mentioned in the report are:
Akashi Therapeutics Inc
Antisense Therapeutics Ltd
Beech Tree Labs Inc
Biogen Inc
Bioleaders Corp
BioMarin Pharmaceutical Inc
Biophytis SAS
Capricor Therapeutics Inc
Catabasis Pharmaceuticals Inc
CRISPR Therapeutics
Cumberland Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Editas Medicine Inc
Eloxx Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
FibroGen Inc
Fulcrum Therapeutics Inc
Galapagos NV
Genethon SA
GTx Inc
Santhera Pharmaceuticals Holding AG
Sarepta Therapeutics Inc
SOM Biotech SL
Strykagen Corp
Summit Therapeutics Plc
Taiho Pharmaceutical Co Ltd
Teijin Pharma Ltd
WAVE Life Sciences Ltd
Note: We can also add companies which are not part of the above list
One of the very important chapter of Duchenne Muscular Dystrophy Drugs market report is competitive analysis. In this chapter, we have presented a detailed overview of the competition and have provided the market revenue of each company along with the market share.
Global Duchenne Muscular Dystrophy Drugs Market Analysis By Type
Development & Drug Target
Mechanism of Action (MoA)
Route of Administration (RoA)
Molecule Type
In the year 2021, Development & Drug Target segment had XX% of market share and in terms of value, the Development & Drug Target market was valued at USD XX Million. It is expected that Development & Drug Target will have XX% of market share by the end of year 2027 and the incremental growth from 2021 till 2027 is expected to be USD XX Million.
Global Duchenne Muscular Dystrophy Drugs Market Analysis By Application
Hospitals and Clinics
Medical Laboratories
Others
Hospitals and Clinics segment is expected to account for XX% of market share by the end of year 2027 from XX% in 2021. The Hospitals and Clinics segment is expected to grow at USD XX million by the end of year 2027.
Regional Analysis
Geographically, the global Duchenne Muscular Dystrophy Drugs market has been categorized as North America, Europe, the Asia-Pacific, the Middle East & Africa, and South America. North America accounted Duchenne Muscular Dystrophy Drugs market accounted for XX% of the market share in the year 2021 and register strong growth during the forecast period. However, the APAC area is experiencing significant growth due to various factors.
Report Scope:
Market Size: XX Million (Ask for Sample in order to view the details)
CAGR: XX% Ask for Sample in order to view the details)
Base Year: 2021
Forecast Period: 2022-2027
Forecast Units: Value (USD Million)
Geographies Covered: North America, Europe, Asia-Pacific, Middle East & Africa, South America
Frequently Asked Questions - FAQ:
What will be the dynamics for the adoption of Duchenne Muscular Dystrophy Drugs market based on Healthcare Industry
Which product will contribute more to the overall market share by 2027
Which region is expected to adopt Duchenne Muscular Dystrophy Drugs offerings at a fast rate
What are the key market dynamics influencing Duchenne Muscular Dystrophy Drugs market growth How will they turn into strengths or weaknesses of companies operating in the market space
|
Table Of Contents:
1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type (2022-2027)
1.3.2 Development & Drug Target
1.3.3 Mechanism of Action (MoA)
1.3.4 Route of Administration (RoA)
1.3.5 Molecule Type
1.4 Market Segment by Application
1.4.1 Global Duchenne Muscular Dystrophy Drugs Market Share by Application (2022-2027)
1.4.2 Hospitals and Clinics
1.4.3 Medical Laboratories
1.4.4 Others
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Duchenne Muscular Dystrophy Drugs Market Size
2.1.1 Global Duchenne Muscular Dystrophy Drugs Revenue 2016-2027
2.1.2 Global Duchenne Muscular Dystrophy Drugs Sales 2016-2027
2.2 Duchenne Muscular Dystrophy Drugs Growth Rate by Regions
2.2.1 Global Duchenne Muscular Dystrophy Drugs Sales by Regions 2016-2021
2.2.2 Global Duchenne Muscular Dystrophy Drugs Revenue by Regions 2016-2021
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
3 Market Share by Manufacturers
3.1 Duchenne Muscular Dystrophy Drugs Sales by Manufacturers
3.1.1 Duchenne Muscular Dystrophy Drugs Sales by Manufacturers 2016-2021
3.1.2 Duchenne Muscular Dystrophy Drugs Sales Market Share by Manufacturers 2016-2021
3.2 Revenue by Manufacturers
3.2.1 Duchenne Muscular Dystrophy Drugs Revenue by Manufacturers (2016-2021)
3.2.2 Duchenne Muscular Dystrophy Drugs Revenue Share by Manufacturers (2016-2021)
3.2.3 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio (CR5 and HHI)
3.3 Duchenne Muscular Dystrophy Drugs Price by Manufacturers
3.4 Key Manufacturers Duchenne Muscular Dystrophy Drugs Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Duchenne Muscular Dystrophy Drugs Market
3.6 Key Manufacturers Duchenne Muscular Dystrophy Drugs Product Offered
3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Development & Drug Target Sales and Revenue (2016-2021)
4.1.2 Mechanism of Action (MoA) Sales and Revenue (2016-2021)
4.1.3 Route of Administration (RoA) Sales and Revenue (2016-2021)
4.1.4 Molecule Type Sales and Revenue (2016-2021)
4.2 Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Type
4.3 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type
4.4 Duchenne Muscular Dystrophy Drugs Price by Type
5 Market Size by Application
5.1 Overview
5.2 Global Duchenne Muscular Dystrophy Drugs Sales by Application
6 United States
6.1 United States Duchenne Muscular Dystrophy Drugs Breakdown Data by Company
6.2 United States Duchenne Muscular Dystrophy Drugs Breakdown Data by Type
6.3 United States Duchenne Muscular Dystrophy Drugs Breakdown Data by Application
7 European Union
7.1 European Union Duchenne Muscular Dystrophy Drugs Breakdown Data by Company
7.2 European Union Duchenne Muscular Dystrophy Drugs Breakdown Data by Type
7.3 European Union Duchenne Muscular Dystrophy Drugs Breakdown Data by Application
8 China
8.1 China Duchenne Muscular Dystrophy Drugs Breakdown Data by Company
8.2 China Duchenne Muscular Dystrophy Drugs Breakdown Data by Type
8.3 China Duchenne Muscular Dystrophy Drugs Breakdown Data by Application
9 Rest of World
9.1 Rest of World Duchenne Muscular Dystrophy Drugs Breakdown Data by Company
9.2 Rest of World Duchenne Muscular Dystrophy Drugs Breakdown Data by Type
9.3 Rest of World Duchenne Muscular Dystrophy Drugs Breakdown Data by Application
9.4 Rest of World Duchenne Muscular Dystrophy Drugs Breakdown Data by Countries
9.4.1 Rest of World Duchenne Muscular Dystrophy Drugs Sales by Countries
9.4.2 Rest of World Duchenne Muscular Dystrophy Drugs Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia
10 Company Profiles
10.1 Akashi Therapeutics Inc
10.1.1 Akashi Therapeutics Inc Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
10.1.4 Duchenne Muscular Dystrophy Drugs Product Introduction
10.1.5 Akashi Therapeutics Inc Recent Development
10.2 Antisense Therapeutics Ltd
10.2.1 Antisense Therapeutics Ltd Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
10.2.4 Duchenne Muscular Dystrophy Drugs Product Introduction
10.2.5 Antisense Therapeutics Ltd Recent Development
10.3 Beech Tree Labs Inc
10.3.1 Beech Tree Labs Inc Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
10.3.4 Duchenne Muscular Dystrophy Drugs Product Introduction
10.3.5 Beech Tree Labs Inc Recent Development
10.4 Biogen Inc
10.4.1 Biogen Inc Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
10.4.4 Duchenne Muscular Dystrophy Drugs Product Introduction
10.4.5 Biogen Inc Recent Development
10.5 Bioleaders Corp
10.5.1 Bioleaders Corp Company Details
10.5.2 Company Description and Business Overview
10.5.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
10.5.4 Duchenne Muscular Dystrophy Drugs Product Introduction
10.5.5 Bioleaders Corp Recent Development
10.6 BioMarin Pharmaceutical Inc
10.6.1 BioMarin Pharmaceutical Inc Company Details
10.6.2 Company Description and Business Overview
10.6.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
10.6.4 Duchenne Muscular Dystrophy Drugs Product Introduction
10.6.5 BioMarin Pharmaceutical Inc Recent Development
10.7 Biophytis SAS
10.7.1 Biophytis SAS Company Details
10.7.2 Company Description and Business Overview
10.7.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
10.7.4 Duchenne Muscular Dystrophy Drugs Product Introduction
10.7.5 Biophytis SAS Recent Development
10.8 Capricor Therapeutics Inc
10.8.1 Capricor Therapeutics Inc Company Details
10.8.2 Company Description and Business Overview
10.8.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
10.8.4 Duchenne Muscular Dystrophy Drugs Product Introduction
10.8.5 Capricor Therapeutics Inc Recent Development
10.9 Catabasis Pharmaceuticals Inc
10.9.1 Catabasis Pharmaceuticals Inc Company Details
10.9.2 Company Description and Business Overview
10.9.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
10.9.4 Duchenne Muscular Dystrophy Drugs Product Introduction
10.9.5 Catabasis Pharmaceuticals Inc Recent Development
10.10 CRISPR Therapeutics
10.10.1 CRISPR Therapeutics Company Details
10.10.2 Company Description and Business Overview
10.10.3 Sales, Revenue and Market Share of Duchenne Muscular Dystrophy Drugs
10.10.4 Duchenne Muscular Dystrophy Drugs Product Introduction
10.10.5 CRISPR Therapeutics Recent Development
10.11 Cumberland Pharmaceuticals Inc
10.12 Daiichi Sankyo Co Ltd
10.13 Debiopharm International SA
10.14 Editas Medicine Inc
10.15 Eloxx Pharmaceuticals Inc
10.16 F. Hoffmann-La Roche Ltd
10.17 FibroGen Inc
10.18 Fulcrum Therapeutics Inc
10.19 Galapagos NV
10.20 Genethon SA
10.21 GTx Inc
10.22 Santhera Pharmaceuticals Holding AG
10.23 Sarepta Therapeutics Inc
10.24 SOM Biotech SL
10.25 Strykagen Corp
10.26 Summit Therapeutics Plc
10.27 Taiho Pharmaceutical Co Ltd
10.28 Teijin Pharma Ltd
10.29 WAVE Life Sciences Ltd
11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 Duchenne Muscular Dystrophy Drugs Sales Channels
11.2.2 Duchenne Muscular Dystrophy Drugs Distributors
11.3 Duchenne Muscular Dystrophy Drugs Customers
12 Market Forecast
12.1 Global Duchenne Muscular Dystrophy Drugs Sales and Revenue Forecast 2022-2027
12.2 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Type
12.3 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Application
12.4 Duchenne Muscular Dystrophy Drugs Forecast by Regions
12.4.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Regions 2022-2027
12.4.2 Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Regions 2022-2027
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Disclaimer
|
TABLES AND FIGURES
Figure Duchenne Muscular Dystrophy Drugs Product Picture
Table Duchenne Muscular Dystrophy Drugs Key Market Segments
Table Major Manufacturers Duchenne Muscular Dystrophy Drugs Covered in This Report
Table Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type 2022-2027 (K Units) & (Million US$)
Figure Global Duchenne Muscular Dystrophy Drugs Sales Market Shar by Type 2016-2027
Figure Development & Drug Target Figures
Table Major Manufacturers of Development & Drug Target
Figure Mechanism of Action (MoA) Figures
Table Major Manufacturers of Mechanism of Action (MoA)
Figure Route of Administration (RoA) Figures
Table Major Manufacturers of Route of Administration (RoA)
Figure Molecule Type Figures
Table Major Manufacturers of Molecule Type
Table Global Duchenne Muscular Dystrophy Drugs Market Share by Application 2022-2027 (K Units)
Figure Hospitals and Clinics Use Case
Figure Medical Laboratories Use Case
Figure Others Use Case
Figure Duchenne Muscular Dystrophy Drugs Report Years Considered
Figure Global Duchenne Muscular Dystrophy Drugs Market Size 2016-2027 (Million US$)
Figure Global Duchenne Muscular Dystrophy Drugs Sales 2016-2021 (K Units)
Table Global Duchenne Muscular Dystrophy Drugs Market Size by Regions 2016-2021 (K Units) & (Million US$)
Table Global Duchenne Muscular Dystrophy Drugs Sales by Regions 2016-2021 (K Units)
Table Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Regions 2016-2021
Figure Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Regions 2016-2021
Figure Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Regions in 2021
Table Global Duchenne Muscular Dystrophy Drugs Revenue by Regions 2016-2021 (Million US$)
Table Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Regions 2016-2021
Figure Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Regions 2016-2021
Figure Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Regions in 2021
Table Market Top Trends
Table Global Duchenne Muscular Dystrophy Drugs Sales by Manufacturers (2016-2021) (K Units)
Table Global Duchenne Muscular Dystrophy Drugs Sales Share by Manufacturers (2016-2021)
Figure Global Duchenne Muscular Dystrophy Drugs Sales Share by Manufacturers in 2021
Table Duchenne Muscular Dystrophy Drugs Revenue by Manufacturers (2016-2021) (Million USD)
Table Duchenne Muscular Dystrophy Drugs Revenue Share by Manufacturers (2016-2021)
Figure Duchenne Muscular Dystrophy Drugs Value Share by Manufacturers in 2021
Table Global Duchenne Muscular Dystrophy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Key Manufacturers Duchenne Muscular Dystrophy Drugs Price (2016-2021) (USD/Unit)
Table Key Manufacturers Duchenne Muscular Dystrophy Drugs Plants/Factories Distribution
Table Key Manufacturers Duchenne Muscular Dystrophy Drugs Area Served
Table Date of Key Manufacturers Enter into Duchenne Muscular Dystrophy Drugs Market
Table Key Manufacturers Duchenne Muscular Dystrophy Drugs Product Type
Table Mergers & Acquisitions, Expansion Plans
Table Global Development & Drug Target Sales and Revenue (2016-2021) (K Units) & (Million US$)
Table Global Mechanism of Action (MoA) Sales and Revenue (2016-2021) (K Units) & (Million US$)
Table Global Route of Administration (RoA) Sales and Revenue (2016-2021) (K Units) & (Million US$)
Table Global Molecule Type Sales and Revenue (2016-2021) (K Units) & (Million US$)
Table Global Duchenne Muscular Dystrophy Drugs Sales by Type (2016-2021) (K Units)
Table Global Duchenne Muscular Dystrophy Drugs Sales Share by Type (2016-2021)
Figure Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2016-2021)
Figure Global Duchenne Muscular Dystrophy Drugs Sales Market Share by Type in 2021
Table Global Duchenne Muscular Dystrophy Drugs Revenue by Type (2016-2021) (Million US$)
Table Global Duchenne Muscular Dystrophy Drugs Revenue Share by Type (2016-2021)
Figure Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type (2016-2021)
Figure Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Type in 2021
Table Duchenne Muscular Dystrophy Drugs Price by Type 2016-2021 (USD/Unit)
Table Global Duchenne Muscular Dystrophy Drugs Sales by Application (2016-2021) (K Units)
Table Global Duchenne Muscular Dystrophy Drugs Sales Share by Application (2016-2021)
Figure Global Sales Duchenne Muscular Dystrophy Drugs Market Share by Application (2016-2021)
Figure Global Sales Duchenne Muscular Dystrophy Drugs Market Share by Application (2016-2021)
Figure United States Duchenne Muscular Dystrophy Drugs Sales Growth Rate 2016-2021 (K Units)
Figure United States Duchenne Muscular Dystrophy Drugs Revenue Growth Rate 2016-2021 (Million US$)
Table United States Duchenne Muscular Dystrophy Drugs Sales by Company (2016-2021) (K Units)
Table United States Duchenne Muscular Dystrophy Drugs Sales Market Share by Company (2016-2021)
Figure United States Duchenne Muscular Dystrophy Drugs Sales Market Share by Company in 2021
Table United States Duchenne Muscular Dystrophy Drugs Sales by Type (2016-2021) (K Units)
Table United States Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2016-2021)
Figure United States Duchenne Muscular Dystrophy Drugs Market Share by Type in 2021
Table United States Duchenne Muscular Dystrophy Drugs Sales by Application (2016-2021) (K Units)
Table United States Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2016-2021)
Figure United States Duchenne Muscular Dystrophy Drugs Market Share by Application in 2021
Figure European Union Duchenne Muscular Dystrophy Drugs Sales Growth Rate 2016-2021 (K Units)
Figure European Union Duchenne Muscular Dystrophy Drugs Revenue Growth Rate 2016-2021 (Million US$)
Table European Union Duchenne Muscular Dystrophy Drugs Sales by Company (2016-2021) (K Units)
Table European Union Duchenne Muscular Dystrophy Drugs Sales Market Share by Company (2016-2021)
Figure European Union Duchenne Muscular Dystrophy Drugs Sales Market Share by Company in 2021
Table European Union Duchenne Muscular Dystrophy Drugs Sales by Type (2016-2021) (K Units)
Table European Union Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2016-2021)
Figure European Union Duchenne Muscular Dystrophy Drugs Market Share by Type
Table European Union Duchenne Muscular Dystrophy Drugs Sales by Application (2016-2021) (K Units)
Table European Union Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2016-2021)
Figure European Union Duchenne Muscular Dystrophy Drugs Market Share by Application
Figure China Duchenne Muscular Dystrophy Drugs Sales Growth Rate 2016-2021 (K Units)
Figure China Duchenne Muscular Dystrophy Drugs Revenue Growth Rate 2016-2021 (Million US$)
Table China Duchenne Muscular Dystrophy Drugs Sales by Company (2016-2021) (K Units)
Table China Duchenne Muscular Dystrophy Drugs Sales Market Share by Company (2016-2021)
Figure China Duchenne Muscular Dystrophy Drugs Sales Market Share by Company in 2021
Table China Duchenne Muscular Dystrophy Drugs Sales by Type (2016-2021) (K Units)
Table China Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2016-2021)
Figure China Duchenne Muscular Dystrophy Drugs Market Share by Type in 2021
Table China Duchenne Muscular Dystrophy Drugs Sales by Application (2016-2021) (K Units)
Table China Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2016-2021)
Figure China Duchenne Muscular Dystrophy Drugs Market Share by Application in 2021
Figure Rest of World Duchenne Muscular Dystrophy Drugs Sales Growth Rate 2016-2021 (K Units)
Figure Rest of World Duchenne Muscular Dystrophy Drugs Revenue Growth Rate 2016-2021 (Million US$)
Table Rest of World Duchenne Muscular Dystrophy Drugs Sales by Company (2016-2021) (K Units)
Table Rest of World Duchenne Muscular Dystrophy Drugs Sales Market Share by Company (2016-2021)
Figure Rest of World Duchenne Muscular Dystrophy Drugs Sales Market Share by Company in 2021
Table Rest of World Duchenne Muscular Dystrophy Drugs Sales by Type (2016-2021) (K Units)
Table Rest of World Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2016-2021)
Figure Rest of World Duchenne Muscular Dystrophy Drugs Market Share by Type in 2021
Table Rest of World Duchenne Muscular Dystrophy Drugs Sales by Application (2016-2021) (K Units)
Table Rest of World Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2016-2021)
Figure Rest of World Duchenne Muscular Dystrophy Drugs Market Share by Application in 2021
Table Rest of World Duchenne Muscular Dystrophy Drugs Sales by Countries (2016-2021) (K Units)
Table Rest of World Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries (2016-2021)
Figure Rest of World Duchenne Muscular Dystrophy Drugs Sales Market Share by Countries in 2021
Table Rest of World Duchenne Muscular Dystrophy Drugs Revenue by Countries (2016-2021) (Million US$)
Table Rest of World Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries (2016-2021)
Figure Rest of World Duchenne Muscular Dystrophy Drugs Revenue Market Share by Countries in 2021
Figure Japan Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2016-2021) (K Units)
Figure Japan Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2016-2021) (K Units)
Figure Korea Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2016-2021) (K Units)
Figure Korea Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2016-2021) (K Units)
Figure India Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2016-2021) (K Units)
Figure India Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2016-2021) (K Units)
Figure Southeast Asia Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2016-2021) (K Units)
Figure Southeast Asia Duchenne Muscular Dystrophy Drugs Revenue Growth Rate (2016-2021) (K Units)
Table Akashi Therapeutics Inc Company Details
Table Akashi Therapeutics Inc Description and Business Overview
Table Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2016-2021)
Table Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales Market Share in Global Market
Table Akashi Therapeutics Inc Recent Development
Table Antisense Therapeutics Ltd Company Details
Table Antisense Therapeutics Ltd Description and Business Overview
Table Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2016-2021)
Table Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Sales Market Share in Global Market
Table Antisense Therapeutics Ltd Recent Development
Table Beech Tree Labs Inc Company Details
Table Beech Tree Labs Inc Description and Business Overview
Table Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2016-2021)
Table Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Sales Market Share in Global Market
Table Beech Tree Labs Inc Recent Development
Table Biogen Inc Company Details
Table Biogen Inc Description and Business Overview
Table Biogen Inc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table Biogen Inc Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2016-2021)
Table Biogen Inc Duchenne Muscular Dystrophy Drugs Sales Market Share in Global Market
Table Biogen Inc Recent Development
Table Bioleaders Corp Company Details
Table Bioleaders Corp Description and Business Overview
Table Bioleaders Corp Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table Bioleaders Corp Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2016-2021)
Table Bioleaders Corp Duchenne Muscular Dystrophy Drugs Sales Market Share in Global Market
Table Bioleaders Corp Recent Development
Table BioMarin Pharmaceutical Inc Company Details
Table BioMarin Pharmaceutical Inc Description and Business Overview
Table BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2016-2021)
Table BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Sales Market Share in Global Market
Table BioMarin Pharmaceutical Inc Recent Development
Table Biophytis SAS Company Details
Table Biophytis SAS Description and Business Overview
Table Biophytis SAS Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table Biophytis SAS Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2016-2021)
Table Biophytis SAS Duchenne Muscular Dystrophy Drugs Sales Market Share in Global Market
Table Biophytis SAS Recent Development
Table Capricor Therapeutics Inc Company Details
Table Capricor Therapeutics Inc Description and Business Overview
Table Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2016-2021)
Table Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Sales Market Share in Global Market
Table Capricor Therapeutics Inc Recent Development
Table Catabasis Pharmaceuticals Inc Company Details
Table Catabasis Pharmaceuticals Inc Description and Business Overview
Table Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2016-2021)
Table Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Sales Market Share in Global Market
Table Catabasis Pharmaceuticals Inc Recent Development
Table CRISPR Therapeutics Company Details
Table CRISPR Therapeutics Description and Business Overview
Table CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Sales Growth Rate (2016-2021)
Table CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Sales Market Share in Global Market
Table CRISPR Therapeutics Recent Development
Table Cumberland Pharmaceuticals Inc Company Details
Table Daiichi Sankyo Co Ltd Company Details
Table Debiopharm International SA Company Details
Table Editas Medicine Inc Company Details
Table Eloxx Pharmaceuticals Inc Company Details
Table F. Hoffmann-La Roche Ltd Company Details
Table FibroGen Inc Company Details
Table Fulcrum Therapeutics Inc Company Details
Table Galapagos NV Company Details
Table Genethon SA Company Details
Table GTx Inc Company Details
Table Santhera Pharmaceuticals Holding AG Company Details
Table Sarepta Therapeutics Inc Company Details
Table SOM Biotech SL Company Details
Table Strykagen Corp Company Details
Table Summit Therapeutics Plc Company Details
Table Taiho Pharmaceutical Co Ltd Company Details
Table Teijin Pharma Ltd Company Details
Table WAVE Life Sciences Ltd Company Details
Figure Duchenne Muscular Dystrophy Drugs Value Chain
Table Duchenne Muscular Dystrophy Drugs Distributors List
Table Duchenne Muscular Dystrophy Drugs Customers List
Table Global Duchenne Muscular Dystrophy Drugs Sales Forecast 2022-2027 (K Units) & (Million US$)
Figure Global Duchenne Muscular Dystrophy Drugs Sales Forecast 2022-2027 (K Units)
Figure Global Duchenne Muscular Dystrophy Drugs Revenue Forecast 2022-2027 (Million US$)
Table Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Type 2022-2027 (K Units)
Figure Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Type 2022-2027 (K Units)
Figure Global Duchenne Muscular Dystrophy Drugs Sales Market Share Forecast by Type 2022-2027
Table Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Application 2022-2027 (K Units)
Figure Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Application 2022-2027 (K Units)
Figure Global Duchenne Muscular Dystrophy Drugs Sales Market Share Forecast by Application 2022-2027
Table Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Regions 2022-2027 (K Units)
Figure Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Regions 2022-2027 (K Units)
Figure Global Duchenne Muscular Dystrophy Drugs Sales Market Share Forecast by Regions 2022-2027
Table Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Regions 2022-2027 (K Units)
Figure Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Regions 2022-2027 (K Units)
Figure Global Duchenne Muscular Dystrophy Drugs Revenue Market Share Forecast by Regions 2022-2027
Figure United States Duchenne Muscular Dystrophy Drugs Sales Forecast 2022-2027 (K Units)
Figure United States Duchenne Muscular Dystrophy Drugs Revenue Forecast 2022-2027 (Million US$)
Figure European Union Duchenne Muscular Dystrophy Drugs Sales Forecast 2022-2027 (K Units)
Figure European Union Duchenne Muscular Dystrophy Drugs Revenue Forecast 2022-2027 (Million US$)
Figure China Duchenne Muscular Dystrophy Drugs Sales Forecast 2022-2027 (K Units)
Figure China Duchenne Muscular Dystrophy Drugs Revenue Forecast 2022-2027 (Million US$)
Figure Japan Duchenne Muscular Dystrophy Drugs Sales Forecast 2022-2027 (K Units)
Figure Japan Duchenne Muscular Dystrophy Drugs Revenue Forecast 2022-2027 (Million US$)
Figure Korea Duchenne Muscular Dystrophy Drugs Sales Forecast 2022-2027 (K Units)
Figure Korea Duchenne Muscular Dystrophy Drugs Revenue Forecast 2022-2027 (Million US$)
Figure India Duchenne Muscular Dystrophy Drugs Sales Forecast 2022-2027 (K Units)
Figure India Duchenne Muscular Dystrophy Drugs Revenue Forecast 2022-2027 (Million US$)
Figure Southeast Asia Duchenne Muscular Dystrophy Drugs Sales Forecast 2022-2027 (K Units)
Figure Southeast Asia Duchenne Muscular Dystrophy Drugs Revenue Forecast 2022-2027 (Million US$)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
|